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Abstract: Chemical investigation of the aerial parts of Ammania aegyptiaca ethanol extract (AEEE)
showed high concentrations of polyphenol and flavonoid content, with notable antioxidant activity.
Undescribed acylated diglucoside flavonol myricetin 3-O-β-4 C1 -(600 -O-galloyl glucopyranoside) 7-Oβ-4 C1 -glucopyranoside (MGGG) was isolated from the aerial parts of AEEE, along with four known
polyphenols that had not been characterized previously from AEEE. The inhibitory effects of MGGG,
AEEE, and all compounds against α-amylase, pancreatic lipase and β-glucosidase were assessed. In
addition, molecular docking was used to determine the inhibition of digestive enzymes, and this
confirmed that the MGGG interacted strongly with the active site residues of these enzymes, with
the highest binding free energy against α-amylase (−8.99 kcal/mol), as compared to the commercial
drug acarbose (−5.04 kcal/mol), thus justifying its use in the potential management of diabetes.
In streptozotocin (STZ)-induced diabetic rats, AEEE significantly decreased high serum glucose,
α-amylase activity and serum liver and kidney function markers, as well as increasing insulin blood
level. Moreover, AEEE improved the lipid profile of diabetic animals, increased superoxide dismutase
(SOD) activity, and inhibited lipid peroxidation. Histopathological studies proved the decrease in
pancreas damage and supported the biochemical findings. These results provide evidence that AEEE
and MGGG possess potent antidiabetic activity, which warrants additional investigation.
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1. Introduction
Diabetes mellitus (DM) is a major metabolic disorder leading to high morbidity and
mortality rates around the world [1]. The incidence of diabetes in developing countries has
reached epidemic proportions, and the International Diabetes Federation (IDF) expects an
increase from 382 million people with diabetes to 592 million between 2013 and 2035 [2].
Diabetes is characterized by elevated plasma glucose concentrations, which are caused
by insufficient insulin, insulin resistance, or both. In addition, abnormalities in various
metabolic pathways [3]. As the disease progresses, it results in complications such as
retinopathy, neuropathy, nephropathy, stroke, ischemic heart disease, peripheral vascular
disease, and a variety of heterogeneous diseases [4], more than 95% of which are type 2
diabetes (T2D). It develops as a result of insulin resistance and pancreatic β-cell dysfunction,
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resulting in hyperglycemia [5]. Interestingly, there is a direct link between T2D and
obesity. Obesity leads to increased cytokine production, fat deposition in body tissues
and mitochondrial dysfunction, which results in insulin resistance and pancreatic β-cell
apoptosis [6].
The current treatment for T2D is the usage of oral hypoglycemic drugs. Insulin
replacement therapy is the main treatment for patients with type 1 diabetes [7]. However,
the undesirable effects of such drugs create the need for alternative therapies with no side
effects [8].
As a consequence, there is a growing interest in phytomedicine; plant extracts can
be safer, easily available and affordable and have less incidence of adverse effects in
comparison to synthetic antihyperglycemic drugs [9].
One beneficial approach to the management of diabetes is to reduce post-prandial
hyperglycemia and prevent lipid digestion and absorption. This is clearly associated with
the preclusion of obesity and obesity-related diseases [10]. Exploring the natural inhibitors
of hydrolyzing enzymes in carbohydrate and lipid digestion may provide an attractive
combinatorial therapeutic strategy for the management/prevention of post-prandial hyperglycemia and obesity. Moreover, DM appears to be an oxidative stress-related endocrine
disorder, and using antioxidants may be beneficial in its prophylaxis and treatment [11].
The aforementioned studies reported that, in T2D, oxidative stress is increased due to
chronic hyperglycemia, leading to the manufacturing of reactive oxygen species (ROS) in
β-cells, thereby decreasing antioxidant activity via the enhancement of free radical generation [12]. Consequently, medicinal plants rich in antioxidant phytoconstituents can shield
β-cells from reactive oxygen species (ROS) and avoid diabetes induced by ROS [13].
Increasing evidence suggests that plant polyphenols may have therapeutic antioxidant
activities, which are related to their capacity to scavenge a wide range of ROS [14]. Thus,
a relevant source of plant phenolics, as potential therapeutic agents that can be used to
decrease blood glucose levels and lipids for the dual control of diabetes and obesity via
digestive enzyme inhibition, specifically pancreatic α-amylase, intestinal β-glucosidase
and pancreatic lipase inhibition [15], along with its ability to boost the body’s antioxidant
system, has become an absolute necessity.
One of the famous plant genera that include phenolic-rich species is the genus Ammannia (Lythraceae). This genus is known to include species capable of synthesizing and
accumulating a high percent of phenolics [16]. Ammannia baccifera L. subsp. aegyptiaca
(Willd.) Koehne Waste (AE) is an annual herb distributed in tropical regions. In Egypt,
it has been recorded in the Nile and Oasis geographical regions. It grows as a summer
weed in rice fields, ditches and swamps [17]. This term is often used as a synonym for
a variety of subspecies of Ammannia baccifera L., e.g., [18]. However, AE is an accepted
species separated from the other three species known from Egypt by its sessile or subsessile
flowers in compact axillary cymes. The type specimen of this species was collected from
Damietta, Egypt [17]. In the available current literature, the phenolic profile and biological
activities of AE have never been investigated. However, other species have been reported
to have antidiabetic activity [19].
This study aimed to subject the flowering whole plant ethanol extract (AEEE) of AE
to an intensive phytochemical investigation of its phenolic constituents and investigate
the in vitro antioxidant activity of AEEE and the isolated constituents, along with an
evaluation of their inhibitory effects and antidiabetic activity against the extra-pancreatic
digestive enzymes and, thereby, potential antidiabetic activity. Molecular docking analysis
was used to demarcate the activity of the tested compounds against digestive enzymes.
Previous studies reported that phenolic compounds and flavonoids were able to bind to the
pockets of α-amylase, β-glucosidase and pancreatic lipase, forming enzyme-inhibitors
complexes [20–22]. Furthermore, the researchers evaluated the potential antidiabetic
activity of the flowering whole plant AEEE in diabetic rats in order to assess its antidiabetic
effects. This provides related data for further study regarding its utilization as an adjuvant
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therapy in the management of T2D. As the plant is a weed that mainly threatens water
channels and rice fields, this study has focused on the exploitation of this plant waste.
2. Results
2.1. Total Phenolic and Flavonoid Contents
The phenolic content of AEEE was determined to be 380.5 ± 3.88 mg GAE/g, where
R2 = 0.9985, and the equation for standard curve was Y = 0.0242x + 0.0211. In addition,
the total flavonoid content in the AEEE was evaluated as 190 ± 2.31 mg CE/g, where
R2 = 0.9989, and the equation for the standard curve was Y= 0.0048x + 0.0091. Thus, AEEE
was found to be a source of a wide range of potent polyphenolic constituents.
2.2. Identification of Polyphenols from AEEE
A concentrated aqueous ethanol extract (3:1) of AEEE was prepared from fresh aerial
samples of AE. The AEEE was fractionated over column chromatography on a Sephadex
LH 20 using water/methanol mixtures of decreasing polarities. This was followed by
the column fractionation of the 30 and 50% aqueous methanol Sephadex LH 20 column
fractions over MCI gel, which afforded pure samples of compounds (1–5). The known
compounds (2–5) showed chromatographic, UV absorption and hydrolytic data identical
with those reported for kaempfeol 3-O-rutinoside 2 [23], quercetin 3-O-rutinoside 3 [24],
tellimagranidine-I 4 [16] and 2,3-α,β-digalloy glucose 5 [25], respectively (Figure 1).
Compound 1, a yellow amorphous powder, showed chromatographic properties (dark
purple spot on paper chromatogram under UV light, turning reddish-orange when fumed
with ammonia vapor and moderate migration in aqueous and organic solvents). The UV
spectral analysis of 1 in methanol and upon the addition of shift reagents [16] confirmed
the presence of a flavonol moiety, with a free hydroxyl at the C-40 position (stable NaOMe
spectrum) and a substituted hydroxyl at the C-7 position (showed no shift in UV with
NaOAc). UV: λmax (MeOH), (nm): 256, 356; +NaOAc: 257, 358; +NaOAc+H3 BO3 : 268, 390;
+AlCl3 : 269, 395; +AlCl3 +HCl: 271, 303, 401; NaOMe: 253, 404 nm. The acid hydrolysis of 1
yielded glucose (co-chromatography), myricetin and gallic acid (co-chromatography and
1 H NMR). A negative ESI/MS for 1 was consistent with this view and showed a molecular
ion peak at [M–H]− : 793.27, consistent with a molecular mass of 794. Structure 1 and the
site of attachment of the galloyl moiety to the 3-O-glucoside moiety were confirmed by
NMR analysis.1 H NMR spectrum of 1 (DMSO-d6 ) showed two anomeric hexose proton
signals at δ ppm and 5.35 and 5.02, each with (d, J = 8.5 Hz), corresponding to the anomeric
glucoside moieties at the 3- and 7-positions of the flavonol moiety, respectively. In addition,
the spectrum revealed a pair of methylene glucose proton signals at δ 4.26 (d, J = 12 Hz)
and 4.12 (m), which were attributable to two 600 - glucose carbons whose germinal hydroxyl
groups are acylated by the galloyl moiety. The signals of the two methylene protons in
the 7-O-glucoside moiety and the remainder of the glucose protons overlapped with the
water protons’ signal and showed an up-field shift to the region from δ 3.3 to 3.9. The
characteristic protons of the galloyl moiety displayed a singlet signal at δ 7.02. In addition,
the 7-O-substituted myricetin moiety was evidenced by proton signals at δ 6.3 (d, J = 2.5 Hz)
and 6.75 (d, J = 2.5 Hz), which can be attributed to the H-6 and H-8 of this moiety [16]. 13 C
NMR of 1 confirmed its structure. It exhibited twelve glucose carbon signals.
The two β-glucose anomers at positions C-7 and C-3 were detected from the downfield
resonances at δ ppm 99.3 and 102.9, respectively, while the methylene C-6 000 glucose
carbon with a free hydroxyl and the acylated methylene glucose C-6 00 carbon were found
resonating up-field, at δ ppm 60.2 and 63.2, respectively. Acylation by gallic acid resulted
in the de-shielding of the second resonance. The remaining glucose carbons were found
resonating at a δ ppm value close to that of the flavonol 3,7-di-O-glycoside [16]. The
presence of only one galloyl moiety in 1 followed from the single carboxyl carbon resonance
at δ 166.5 and from the recognized, characteristic pattern of the remaining galloyl carbons.
Substitutions at the 3- and 7-positions of myricetin were evidenced by the relative up-field
shifts of the C-3 and C-7 signals to δ 134.4 and 161.6, respectively. Down-field shifts in the
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signals were detected corresponding to the o- and p-carbons of the flavonol moiety in 1, in
comparison with the corresponding signals in free myricetin [16].

Compound (1)

Compound (3)

Compound (2)

Compound (4)

Compound (5)
4

Fig.1. Myricetin3-O-βC1-(6′′-O-galloylglucopyranoside)-7-O-β-4C1-glucopyranoside (1),
Figure 1.
Myricetin3-O-β-4 C1 -(600 -O-galloylglucopyranoside)-7-O-β-4 C1- glucopyranoside (1),
kaempfeol kaempfeol
3-O-rutinoside
(2), quercetin 3-O-rutinoside (3), tellimagranidine-I (4) and 2,3-α,β3-O-rutinoside (2), quercetin 3-O-rutinoside (3), tellimagranidine-I (4) and 2,3-α, β-digalloy
digalloy glucose
(5).
glucose (5).
Furthermore, the 4 C1 conformation of the two glucose moieties was confirmed by the
measured chemical shift values of the carbon resonances. The above data confirm that
the substitution pattern in 1 is typical of that present in quercetin 3-O-β-4 C1 -(600 -O-galloyl
glucopyranoside)-7-O-β-4 C1 -glucopyranoside, which was previously isolated from the
same plant extract [16]. That the galloylated glucose linked to the hydroxyl group at C-3
of the aglycone was unambiguously confirmed by a 3 J long-range correlation between
its anomeric proton (δ ppm 5.35) and C-3 (δ ppm 134.4) of the myricetin moiety in the
hetronuclear multi bond connectivity (HMBC) spectrum. This spectrum also showed a cross
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peak correlating to the second anomeric proton resonance at δ 5.02 to the myricetin carbon
C-7 at δ ppm 161.6. Consequently, 1 is identified as myricetin 3-O-β-4 C1 -(600 -O-galloyl
glucopyranoside)-7-O-β-4 C1 -glucopyranoside, which has not been reported previously in
nature Figure 1.
2.3. Molecular Docking
Computational docking studies were utilized to predict the binding mode, affinity and
binding free energy (∆G) of the tested compounds with pancreatic α-amylase, intestinal
β-glucosidase and pancreatic lipase. All the molecular docking results regarding interactions between the isolated compounds (1–5), reference standards and three digestive
enzymes’ binding sites, with some relevant parameters, are summarized in Tables 1–3 and
Figures 2–4.
Table 1. Analysis results of isolated compounds (1–5) against (human pancreatic α-amylase) target site
PDB ID: 2QV4.
Ligand

RMSD Value (Å)

Docking Score (kcal/mol)

Interactions and Residues

•

Acarbose

1.99

Hydrogen bonding:
Thr163
His305
His201
Asp300

−8.131
•

1.98

−8.99

•

π- interactions:
His305
Trp59
Ile235
Lleu162

•

Compound 2

1.94

Hydrogen bonding:
His101
Asp197
Asp300
Gln63
Thr163

−7.07

•

-

Hydrogen bonding:
Asp300
Asp197

Compound 1

2.42
2.67
1.97
2.37
1.83
1.97

π- interactions:
Leu165
His101

•

Distance (Å)

π- interactions:

2.84
2.17
2.31
-

2.45
2.24
1.97
2.15
3.08
2.69
-

Leu162

•

Compound 3

1.69

Hydrogen bonding:
His101
Asp197
Thr163

−6.43
•

π- interactions:
Leu162,Asp300,Val107

2.72
1.83
2.11
-
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Table 1. Cont.
Ligand

RMSD Value (Å)

Docking Score (kcal/mol)

Interactions and Residues

•

Compound 4

His101
Asp300
Gln63

−6.47

2.39

Hydrogen bonding:

•

π- interactions:

Distance (Å)
2.98
2.46
2.54
2.23
4.85
-

Tyr151

•

Compound 5

Tyr62
Gln63
Tyr151
Glu233
His305
Tyr163

−6.50

1.88

Hydrogen bonding:

•

π- interactions:

2.01
3.06
2.85
2.52
2.33
1.83

-

Leu165,Leu162.Ala198,Ile235

Table 2. Analysis results of isolated compounds (1–5) against (human β-glucosidase) target site PDB
ID: 2ZOX.
Ligand

RMSD Value (Å)

Docking Score (kcal/mol)

Interactions and Residues

•
Acarbose

1.77

Lys278
Asn319
Gln271
Ser270
Glu331

−5.04

•

Compound 1

1.88

Hydrogen bonding:

•

2.68
2.50
2.82
2.68
2.36

Hydrogen bonding:
Lys321
Glu318
Asn319
Met275
Gln279
Lys278
Gln271

−6.43

Distance (Å)

π- interactions:

2.12
2.41
2.28
2.65
2.94
2.90
2.91
2.78
-

Met275,Lys278

•
Compound 2

2.03

−5.28

Hydrogen bonding:
Tyr316
Glu331
Asn319
Lys278

1.92
2.22
2.73
2.10
2.46
2.74
2.02
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Table 2. Cont.
Ligand

RMSD Value (Å)

Docking Score (kcal/mol)

Interactions and Residues

•

Compound 3

Glu318
Lys278
Gln271
Tyr316
Glu241
Arg245

−5.42

2.56

•
Compound 4

Hydrogen bonding:
Lys320
Lys278

−5.36

1.68

Hydrogen bonding:

•

π- interactions:

Distance (Å)
2.10
2.50
2.04
5.02
1.93
2.24
3.07
3.07
5.26
3.34
2.81
-

Tyr316

•

Compound 5

Glu318
Ser238
Lys315
Gln271
Lys278

−5.70

1.18

Hydrogen bonding:

•

π- interactions:

1.96
1.98
2.41
2.78
2.22
2.85
2.29
-

Glu331

Table 3. Analysis results of isolated compounds (1–5) against (human pancreatic lipase) target site PDB
ID: 2OXE.
Ligand

RMSD Value (Å)

Docking Score (kcal/mol)

Interactions and Residues

•

Orlistat

1.24

Hydrogen bonding:
Gln388
Asn385

−6.66
•

Compound 1

1.78

•

-

Hydrogen bonding:
Asn353
Glu350
Thr355
Asp409
Asn295

−7.70

2.85
2.26

π- interactions:
Leu463
Lys419

•

Distance (Å)

π- interactions:
Asp409

1.96
1.83
2.13
2.79
2.61
-
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Table 3. Cont.
Ligand

RMSD Value (Å)

Docking Score (kcal/mol)

Interactions and Residues

Distance (Å)

Hydrogen bonding:

2.88
2.02
2.88
2.20
2.49

•
Compound 2

1.99

Glu350
Ser351
Asp409
Thr355

−7.20

•

Compound 3

1.60

Hydrogen bonding:
Asn385
Thr355
Asp409
Glu350
Asn353
Asn295
Asn411
Asp297

−7.39

•

3.10
2.38
2.07
2.06
2.42
2.14
2.38
2.87
-

π- interactions:
Phe410

•

Compound 4

Compound 5

2.16

2.03

−5.43

−5.51

Hydrogen bonding:
Asn411
Gln384
Thr355
Asp409
Ser351
Glu350

-

2.34
2.88
2.08
2.09
2.15
2.98
2.03
3.02
2.01
1.92
2.5

2.3.1. Interactions Analysis with α-Amylase
In accordance with the in vitro studies, the docking results indicated that compounds
(1–5) bind to the enzyme active site with the lowest binding energies of −8.99, −7.07, −6.43,
−6.47 and −6.50 kcal/mol, respectively (Figure 2). Compounds 1, 4 and 5 were the first to
be reported as inhibitory against α-amylase.
Among all isolates, MGGG exhibited the highest docking score (−8.99 kcal/mol),
which is higher than that of the reference standard, acarbose (−8.13 kcal/mol). The binding
of MGGG to α-amylase was greater than those of β-glucosidase and pancreatic lipase
(−6.43 and −7.70 kcal/mol, respectively).
The active site of α-amylase consists mainly of Ala198, Asp197, Glu233, His201, His299,
Tyr62, Asp300, Thr163, His101 and His305 [26]. As shown in Figure 2, all these residues
participated in the binding of the enzyme to the docked compounds.
The hydroxyl groups at C-5 and C-6 of the valienamine moiety of the reference
standard, acarbose, formed two hydrogen bonds with Thr163. In addition, the C-2 hydroxyl
group in the O-4,6-dideoxy α-D-glucopyranosyl moiety interacted with Asp300 via a
hydrogen bond. The methyl group in the O-4,6-dideoxy α-D-glucopyranosyl moiety
interacted with Leu165 and His101 by forming Pi-alkyl interactions. Furthermore, the C-2,
C-3 and C-6 hydroxyl groups in the O-α-D-glucopyranosyl moiety formed three hydrogen
bonds with His305, Asp300 and His201 (Figure 2a).
In MGGG, the C-2, C-3 and C-4 sugar hydroxyl groups of the galloylated glucose
moiety formed three hydrogen bonds with Asp300 and Asp197, while the chromone ring
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formed two Pi–alkyl interactions with Ile235 and Leu162. On the other hand, the galloyl
moiety interacted with Trp59 via a Pi–Pi interaction, and the flavonol B-ring formed another
Pi–Pi interaction with His305 (Figure 2b).

a

b

c

d

e

f

Figure 2. Molecular docking interactions of isolated compounds (1–5) with amino acid residues
in the active site of α-amylase as 3D diagram. (a) Standard Acarbose (b) MGGG (c) Kaempfeol
3-O-rutinoside (d) Quercetin 3-O-rutinoside (e) Tellimagranidine-I (f) 2,3-α, β-digalloy glucose. The
green dashed lines stand for hydrogen bonds and the purple dashed lines stand for pi interactions.

2.3.2. Interactions Analysis with β-Glucosidase
Fig. 2. Molecular docking
interactionsthe
of in
isolated
with amino
in the compounds
active site of αConfirming
vitro compounds
results, the(1-5)
docking
scoresacid
for residues
the isolated
1–5
amylase as 3D diagram.
(a)6.43,
Standard
Acarbose
MGGG
3-O-rutinoside
(d) Quercetin
were −
−5.28,
−5.42,(b)
−5.36
and(c)−Kaempfeol
5.70 kcal/mol,
respectively
(Figure 3-O-rutinoside
3). All isolates
(e) Tellimagranidine-I
2,3-α,β-digalloy
glucose.
The greenagainst
dashed β-glucosidase.
lines stand for hydrogen
and the MGGG
purple
were(f)
first
to be reported
as inhibitory
Amongbonds
all isolates,
dashed lines standsexhibited
for pi interactions.
the highest docking score (−6.43 kcal/mol), which is higher than that of the
reference standard, acarbose (−5.04 kcal/mol).
Met275, Lys320, Asn319, Tyr316, Ser274, Gln271, Ser270, Glu331 and Lys278 play a
significant role in binding to the co-crystallized ligand on the active site of β-glucosidase [27].
As shown in Figure 3, all these residues, except Ser270, participated in the binding of the
enzyme to the inhibitor isolates.
The best pose on the part of the reference (acarbose) was found to form five hydrogen
bonds through its hydroxyl groups. The hydroxyl groups attached to C-5 and C-6 of the
valienamine moiety formed two hydrogen bonds with Gln271 and Ser270. Additionally,
the C-2 hydroxyl group in the O-4,6-dideoxy α-D-glucopyranosyl moiety interacted with
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Glu331 via a hydrogen bond. The hydroxyl group attached to C-2 in the terminal α-Dglucose moiety formed a hydrogen bond with Asn319, while the terminal acetal linkage in
acarbose interacted with Lys278 via one hydrogen bond (Figure 3a).

a

b

c

e

d

f

Figure 3. Molecular docking interactions of isolated compounds (1–5) with amino acid residues in
the active site of β-glucosidase as 3D diagram. (a) Standard Acarbose (b) MGGG (c) Kaempfeol
Fig.3. Molecular docking interactions of isolated compounds (1-5) with amino acid residues in the active site of β(d) Quercetin
(e) Tellimagranidine-I
(f)(d)
2,3-α,
β-digalloy
glucosidase as 3D 3-O-rutinoside
diagram. (a) Standard
Acarbose 3-O-rutinoside
(b) MGGG (c) Kaempfeol
3-O-rutinoside
Quercetin
3-O- glucose. The
green dashed(f)lines
stand for hydrogen
bonds
and
the purple
dashed
lines stand
forand
pi interactions.
rutinoside (e) Tellimagranidine-I
2,3-α,β-digalloy
glucose. The
green
dashed
lines stand
for hydrogen
bonds
the purple dashed lines stands for pi interactions.

On the other hand, regarding the new isolate, the C-4 sugar hydroxyl group in the
galloylated glucose moiety formed a hydrogen bond with Glu318, while the galloyl moiety
interacted with Lys278 and Gly271 via two hydrogen bonds and with Lys287 via Pi–cation
interaction. Additionally, B-ring hydroxyl groups formed four hydrogen bonds with
Asn319, Met275, Gln279 and Lys278, as well as a Pi–sulfur interaction with Met275, While
the C-3hydroxyl group in the 7-O-β-glucopyranoside moiety formed a hydrogen bond
with Lys321, the chromone ring formed two Pi–alkyl interactions with Lys320 (Figure 3b).
The docking results confirmed that MGGG had similarities with acarbose because they
interacted with several key amino acids residues of β-glucosidase, Lys278, Asn319 and
Gln271, suggesting that those three amino acid residues may play an important role in the
inhibitory activities of these two compounds.
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2.3.3. Interactions Analysis with Pancreatic Lipase
The isolated compounds (1–5) were able to bind to the active site of pancreatic lipase.
The binding free energy values were −7.70, −7.20, −7.39, −5.43 and −5.51 kcal/mol,
respectively, confirming the in vitro data (Figure 4). All isolates were first to be reported as
inhibitory against pancreatic lipase except compound (3) [21].

Figure 4. Molecular docking interactions of isolated compounds (1–5) with amino acid residues in

Fig.4. Molecular docking interactions of isolated compounds (1-5) with amino acid residues in the active site of
the active site of pancreatic lipase as 3D diagram. (a) Standard Acarbose (b) MGGG (c) Kaempfeol
pancreatic lipase as 3D diagram. (a) Standard Acarbose (b) MGGG (c) Kaempfeol 3-O-rutinoside (d) Quercetin 3-O3-O-rutinoside(f)(d)
Quercetin 3-O-rutinoside
(e)green
Tellimagranidine-I
(f) 2,3-α,
β-digalloybonds
glucose.
rutinoside (e) Tellimagranidine-I
2,3-α,β-digalloy
glucose. The
dashed lines stand
for hydrogen
and The
green
dashed
lines
stand
for
hydrogen
bonds
and
the
purple
dashed
lines
stand
for
pi
interactions.
the purple dashed lines stands for pi interactions.
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The key residues of pancreatic lipase’s active pocket are Asn383, Asn353, Glu350,
Asn385, Asp409, Lys419, Leu463, Thr355, Ser 351, Gln388, and Lys 387 [28]. As shown
in Figure 4, all these residues, except Gln388, Leu463 and Lys419, participated in the
enzyme-inhibitor complexes.
Among all the isolates, MGGG exhibited the highest docking score (−7.70 kcal/mol),
Plants 2022, 11, x FOR PEER REVIEW
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Figure 5. Mapping surface showing MGGG occupying the active pocket of α-amylase (a), β-glucoFigure(b)
5. and
Mapping
surface
MGGG occupying the active pocket of α-amylase (a), βsidase
pancreatic
lipaseshowing
(c), respectively.
glucosidase (b) and pancreatic lipase (c), respectively.

2.4. In Vitro Studies
2.4.1. DPPH Assay
The antioxidant activity of AEEE, MGGG and the isolated compounds (2–5) were
evaluated via DPPH assay. The IC50 values were 6.12 ± 0.83 µ g/mL, 2.37 ± 0.56 µ g/mL, >
100 ± 13.67 µ g/mL, 8.81 ± 1.05 µ g/mL, 4.64 ± 0.39 µ g/mL and 4.81 ± 0.73 µ g/mL, respec-
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The antioxidant activity of AEEE, MGGG and the isolated compounds (2–5) were
evaluated via DPPH assay. The IC50 values were 6.12 ± 0.83 µg/mL, 2.37 ± 0.56 µg/mL,
>100
± 13.67
µg/mL, 8.81 ± 1.05 µg/mL, 4.64 ± 0.39 µg/mL and 4.81 ± 0.73 µg/mL, re2.4.2.
ORAC
Assay
spectively, as compared to Vitamin C (the positive control), with an IC50 of 1.83 ±1.41 µg/mL,
The antioxidant activity of AEEE, MGGG, and the separated compounds (2–5) was
reflecting the potent antioxidant activity of MGGG.

evaluated using the more specialized ORAC assay. The IC50 values were 5.92 ± 1.03 µg/mL,
Assay
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new2.01
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4.43 ± 0.68 µg/mL respectively. All values were lower than that of Trolox (the positive
control), which had an IC50 of 28.0 ± 14.31µg/mL, further endorsing the potent antioxidant
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of the new MGGG.

The reducing power of phenolic compounds suggests their antioxidant activity. In
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activity,
with
a
reducing
power
comparable
to
that
of
standard
quercetin.
(2–5) had concentration-dependent reducing power. Additionally, MGGG showed the
2.4.3. Reducing Power Assay

highest activity, with a reducing power comparable to that of standard quercetin.

Figure 6. Reducing power of AEEE and isolated compounds (1–5) compared with quercetin as

Figure
6. Reducing
power
AEEE±and
compounds
standard.
Results are
givenof
as mean
SD ofisolated
three replicate
analyses.(1–5) compared with quercetin as
standard. Results are given as mean ± SD of three replicate analyses.
2.4.4. In Vitro Enzyme Assays
the Enzyme
current study,
AEEE and its isolated compounds exhibited anti-α-amylase,
2.4.4. In In
Vitro
Assays
anti-β- glucosidase and anti-pancreatic lipase activities (Table 4).

In the current study, AEEE and its isolated compounds exhibited anti-α-amylase,
anti-β- glucosidase and anti-pancreatic lipase activities (Table 4).
Table 4. Effect of different tested compounds in the three different enzyme inhibition assays.

Tested Sample
AEEE
MGGG
Kaempferol 3-O-rutinoside

α-Amylase Inhibition at 300 µg/mL
% Inhibition
89.02 ± 2.31
91.36 ± 2.45
80.37 ±3.81*

IC50 µg/mL
176.3 ± 4.21
157.54 ±5.9
206.89 ± 5.60

p Value
<0.0001
<0.0001
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Table 4. Effect of different tested compounds in the three different enzyme inhibition assays.
α-Amylase Inhibition at 300 µg/mL
p Value

Tested Sample

% Inhibition

IC50 µg/mL

AEEE

89.02 ± 2.31

176.3 ± 4.21

MGGG

91.36 ± 2.45

157.54 ± 5.9

<0.0001

Kaempferol 3-O-rutinoside

80.37 ± 3.81 *

206.89 ± 5.60

<0.0001

Quercetin 3-O-rutinoside

72.13 ± 3.49

223.6 ± 3.90

<0.0001

Tellimagranidine-I

78.92 ± 4.13

217.35 ± 5.30

<0.0001

2,3-α, β-digalloy glucose

78.04 ± 1.15

216.89 ± 5.50

<0.0001

Acarbose 300 ug/mL

93 ± 1.80

71.85 ± 3.70

<0.0001

β-glucosidase inhibition at 300 µg/mL
AEEE

88.13 ± 1.25

76.12 ± 2.25

<0.0001

MGGG

92.70 ± 1.42 *

72.77 ± 2.67

<0.0001

Kaempferol 3-O-rutinoside

47 ± 4.79 *

140.33 ± 5.20

<0.0001

Quercetin 3-O-rutinoside

66 ± 3.47 *

104 ± 3.80

<0.0001

Tellimagranidine-I

58.44 ± 3.61 *

115.21± 4.90

<0.0001

2,3-α, β-digalloy glucose

68.43 ± 2.30 *

100.23 ± 3.80

<0.0001

Acarbose at 600 µg/mL

95.2 ± 2.30

110.6 ± 3.20

<0.0001

Pancreatic Lipase Inhibition at 100 µg/mL
AEEE

79 ±3.21

45 ±5.11

MGGG

87 ± 2.38 *

32 ± 4.43 *

<0.0001

Kaempferol 3-O-rutinoside

35.81 ± 3.84 *

135.8 ± 4.30 *

<0.0001

Quercetin 3-O-rutinoside

82.17 ± 2.53 *

40.42 ± 2.41 *

<0.0001

Tellimagranidine-I

19.52 ± 4.36 *

270.1 ± 6.20 *

<0.0001

2,3-α,β-digalloy glucose

18.69 ± 3.10 *

265.95± 4.71 *

<0.0001

57 ± 4.50

3.22 ± 1.30

<0.0001

Orlistat 100 ug/mL

Data are presented as % of inhibition ± S.D. and IC50 ± S.D; *: indicates significant difference in % of inhibition
between AEEE and its isolated compounds.

2.5. In Vivo Assays
2.5.1. Acute Oral Toxicity
The oral administration of AEEE showed no signs of toxicity or mortality, with no
significant changes in neurological and behavioral responses in any tested group during
the 48 h study at up to 2000 mg/kg body weight of the extract. Therefore, doses of 250 and
500 mg/kg were selected for subsequent antidiabetic studies.
2.5.2. Effect of AEEE on Body Weight
Treatment with AEEE at 500 mg/kg body weight significantly inhibited the reduction
in the body weight induced by STZ, as compared to DC (Figure 7A).
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2.5.6. Effect of AEEE on Oxidative Stress Markers of the Pancreas
A remarkable increase in antioxidant enzyme activity (SOD) and a significant reduction
in TBARS manufacture in pancreatic tissues of the DC group versus NC group was observed
(Figure 8). The AEEE-treated diabetic groups exhibited increased SOD activity and the
significantly suppressed formation of TBARS in comparison with the DC group. The
percentage changes from diabetic groups for the 250 and 500 mg/kg doses were 71.6,
42.78, 80.9, and 47.45, respectively. Furthermore, there was a significant difference between
the AEEE-treated diabetic groups and the glibenclamide group (VI) in oxidative stress
parameters (Figure 8C).
2.5.7. Effect of AEEE on Pancreas Histopathological Examination
The pancreas histopathological examination of the NC, AE500-NC and AE250-NC
groups showed a normal image (Figure 9A–C). The Islets of Langerhans appear as circular
shapes with a normal cell lining, while the exocrine components and the interlobular duct
Plants 2022, 11, x FOR PEER REVIEWsurrounded with the supporting tissue appeared well organized and to have a normal
18 of 28
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Figure 9. The histological investigation of pancreas. (A,B,C): Pancreas sections of NC, AE500-NC
Figure 9. The histological investigation of pancreas. (A–C): Pancreas sections of NC, AE500-NC
and
AE 250-NC groups respectively, showing dense staining acinar cells and a light-staining islet
and
AE 250-NC(D):
groups
respectively,
showing
densecells
staining
acinar
a light-staining
islet
of
Langerhans;
Diabetic
rat showing
the acinar
around
the cells
isletsand
though
seemed to be
in
of
Langerhans;
(D):
Diabetic
rat
showing
the
acinar
cells
around
the
islets
though
seemed
to
be
in
normal proportion with up normal morphology with shrunken islet is and intra islet hemorrhage
normal
proportion
with
up
normal
morphology
with
shrunken
islet
is
and
intra
islet
hemorrhage
(blue arrow). (E): Diabetic rat showing degenerative islet of Langerhans (asterisk) with different
vacuoles
size (long
arrow) and
hemorrhage
(short arrow);
AE 500-DC
rat showing
the exo(blue arrow).
(E): Diabetic
rat showing
degenerative
islet (F,G):
of Langerhans
(asterisk)
with different
crine
pancreas
appearing.
vacuoles size (long arrow) and hemorrhage (short arrow); (F,G): AE 500-DC rat showing the exocrine
pancreas appearing.

3. Discussion
3. Discussion
Currently, the search for natural compounds that have both antidiabetic and antioxsearch
natural
that havetoboth
antidiabetic
and antioxidantCurrently,
activities, the
along
withfor
fewer
sidecompounds
effects as compared
traditional
medications,
reidant
activities,
along
with
fewer
side
effects
as
compared
to
traditional
medications,
mains challenging. Polyphenols, particularly flavonoids, are suggested as better therapeutic agents in the management of free radical-mediated diseases, particularly diabetes
mellitus and its chronic complications, due to their potent antioxidant activity, which was
demonstrated both in vitro and in animal model studies [30]. They are hydroxylated phenolic substances, and the hydroxyl group mediates their antioxidant effects by scavenging
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remains challenging. Polyphenols, particularly flavonoids, are suggested as better therapeutic agents in the management of free radical-mediated diseases, particularly diabetes
mellitus and its chronic complications, due to their potent antioxidant activity, which was
demonstrated both in vitro and in animal model studies [30]. They are hydroxylated phenolic substances, and the hydroxyl group mediates their antioxidant effects by scavenging
free radicals via chelating metal ions [31].
Flavonols, with MGGG the sub-class belonging to flavonoids, are effective as antioxidant and antidiabetic agents, mostly due to their chemical structure. Both their configuration and the total number of hydroxyl groups increased both of these activities and
substantially regulated the mechanisms of radical scavenging [32] and antidiabetic effects.
Thus, the total number of hydroxyl groups, hydroxyl configuration, the catechol structure
in the B-ring, the C-2-C-3 double bond, and the C-4 ketonic functional group is essential in
the bioactivity of flavonoids, especially regarding their antidiabetic effect [33]. Myricetin
significantly improves insulin resistance, in addition to its antioxidant, anti-inflammatory
and aldose reductase inhibitory actions [34].
As mentioned above, AE is an annual herb that grows as a summer weed in rice
fields. Despite the reported antidiabetic activity of other Ammannia species, there are no
data in the literature on AE’s phytoconstituents, antidiabetic activity or mechanism of
action. In the current study, a phytochemical investigation of AEEE resulted in the isolation of a unique acylated flavonoid, myricetin 3-O-β-4 C1 -(600 -O-galloyl glucopyranosid)
7-O-β-4 C1 -glucopyranoside, along with four additional known phenolics. A significant
antioxidant potential of AEEE and polyphenols 2–5 was found, and the highest antioxidant potential was exhibited by MGGG, with IC50 values of 2.37 ± 0.56, 2.01 ± 0.23
and 158.13 ± 2.82 µg/mL in comparison to a standard against DPPH, ORAC and ferrous
reducing assay, respectively.
Several reports showed that the radical scavenging capacities increased with an increase in the number of phenolic hydroxyl groups; this was observed for the three classes
of isolated compounds: flavonoids, gallotannins and ellagitannins [35]. Moreover, the
antioxidant activity increased as the number of galloyl units increased; however, it was not
affected by their position or the presence of hemiacetal hydroxyl and 4,6-O-HHDP groups.
Additionally, the presence of two adjacent phenolic hydroxyl groups on the galloyl moiety
was significant, and this was justified by the higher antioxidant capacity of tellimagrandin-I
as compared to nilocitin and the potential of MGGG. Flavonoids with potent antioxidant
activity were shown to be effective in the management of diabetes [36].
The docking results for the tested compounds (1–5) with the digestive enzymes provided solid information about the binding mode, which aligned correctly with the in vitro
experimental results. For instance, the isolates showed a moderate to strong binding mode,
with a docking score (∆G) range from −6.43 to −8.99 kcal/mol. It was observed that the
tested candidates were well accommodated inside the active site of the digestive enzymes,
displaying geometric complementarity and excellent mapping, which increased their inhibitory activity and was involved in various types of interactions with the active site
residues of the target enzymes. In addition, among the tested enzymes, MGGG showed an
RMSD value lower than 2.00 Å, which confirmed its occupancy in the original site of the
crystal ligand.
From the point of view of the molecular structure of MGGG, the presence of multiple
polar hydroxyl groups is very important for the stabilization of candidates inside the
targeted sites of the tested digestive enzymes due to the availability of the electron-donating
groups (-OH) forming an electronegative and electron cloud system inside the pocket,
which can engage in fitted stabilized interactions with polar and charged amino acids. This
justifies the higher inhibitory potential of MGGG as compared to the standard inhibitor
used for digestive enzymes. In addition, the docking results revealed that the hydroxyl
groups of the B-ring, galloyl glucose and β-D-glucopyranose moieties play a central role
in its binding to the digestive enzymes by forming additional hydrogen bonds and Pi
interactions that can fit the new isolate into the targeted pocket, consisting of the common
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amino acids between the reference standard and MGGG in α-amylase (Asp300 and His305)
and β-glucosidase (Lys278, Gln271 and Asn319).
In terms of binding energy and affinity, as compared with the standards orlistat and
acarbose, MGGG showed higher binding free energies for all tested digestive enzymes,
with the highest docking score against α-amylase (∆G= −8.99 kcal mol) and the lowest
docking score against β-glucosidase (∆G= −6.43 kcal mol). While the other candidates
show moderate docking scores in all targets, compound 4 shows weak binding due to its
structural bulkiness, which prevents perfect fitting inside the targeted pocket.
Consequently, the in silico study showed a promising result for the antidiabetic and
anti-obesity drug discovery process. In fact, MGGG may prove to be a potential candidate
for decreasing the activity of digestive enzymes.
The in vivo study showed that glucose levels were significantly reduced and insulin
levels were elevated after the administration of AEEE as compared to the DC group. The
histopathological results further confirmed this, demonstrating that the structural integrity
of the islets of Langerhans was recovered. Furthermore, AEE decreased α-amylase activity.
Phenolics were reported to decrease the activity of digestive enzymes [37,38], and this is in
full agreement with the in vitro assay and molecular docking results.
Pancreatic amylase and intestinal glucosidase are crucial enzymes involved in glucose
formation [39]. β-glucosidases catalyze the breakdown of alkyl and aryl-β-glycosides,
disaccharides and short-chain oligosaccharides via the dual activities of hydrolysis and
transglycosylation [40]. Therefore, the study of β-glucosidase inhibitors is important for
the treatment of type 2 diabetes [41]. However, the effect of inhibitors on β-glucosidase has
been scantly illustrated. The phenolic and flavonoid content in roselle was responsible for
the inhibitory activity α-/β-glucosidase.
Pancreatic α-amylase catalyzes the first step in the starch breakdown. The suppression
of intestinal α-amylase activity hinders starches’ and oligosaccharides’ breakdown into
monosaccharides before absorption. This results in the profound control of T2D. Acarbose,
an oral hypoglycemic agent, is used for the inhibition of α-amylase [42]. Flavonoids such as
myricetin, the core of the new isolate MGGG; luteolin and quercetin were potent inhibitors.
In fact, pancreatic lipase plays a key role in triglyceride absorption in the small intestine [43].
Thereby, the hindrance of triglyceride absorption via lipase inhibition is a major approach
to avoiding obesity and the management of T2D. The commercial drug orlistat strongly
inhibits the activity of pancreatic lipase [44]. Pancreatic lipase-inhibitory activity has
been attributed to various types of phytochemicals, such as saponins, polyphenols and
terpenes [45].
The in vitro enzymatic inhibition results showed that AEEE and all isolates 1–5 possessed antidiabetic and potential anti-obesity activities based on the inhibition of pancreatic
lipase, β-glucosidase and α-amylase. Except for compound 3 [46], AEEE and the isolates (1,
4, 5) were first reported on the three enzymes. Moreover, a significant difference existed
between AEEE and its isolates, as shown in (Table 2). Acylated flavonoids, the class of
the new isolate MGGG and its core (myricetin) were previously reported to have strong
antidiabetic activity [34,47]. In fact, MGGG exhibited the highest percentage of inhibition
in all three enzyme assays, with increased antidiabetic and potential anti-obesity properties
as compared to the reference standards acarbose and orlistat (Table 2). Furthermore, there
was a significant positive correlation between the phenolic content and flavonoid content of
the extract and the α-amylase, β-glucosidase and pancreatic lipase inhibition, with (r = 0.97
p = 0.007 and r = 0.91 p = 0.008) for α-amylase inhibition, (r = 0.93 p = 0.006 and r = 0.90
p = 0.0073) for β-glucosidase inhibition and (r = 0.92 p = 0.005 and r = 0.91 p = 0.006) for
pancreatic lipase inhibition, demonstrating that phenolics and flavonoids may be the main
constituents of the inhibitory effect of AEEE.
In this investigation, an abnormal serum lipid profile was established in diabetic
rats. This agrees with [48,49]. This abnormal serum lipid profile was inverted after the
incorporation of AEEE at both doses. Hence, the extract could be helpful in refining lipid
metabolism, which will, in turn, aid in protection against various diabetic complications.
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The AEEE treatment of the diabetic groups significantly increased SOD activity and
significantly inhibited the creation of TBARS as compared with the DC group. This may
be attributed to its high phenolic and flavonoid content and is in agreement with the
high in vitro antioxidant potentials of both the extract and new isolate according to the
DPPH, ORAC and ferrous reducing assays. Furthermore, AEEE was considered safe
because it decreased the levels of AST, ALT, creatinine and urea as compared to DC. The
biochemical findings are in agreement with the histopathological modifications to the β-cells
of the pancreas. Such histopathological modifications were decreased by the incorporation
of AEEE extract at both doses. The current study agrees with previous studies on the
antidiabetic effects of herbal extracts [50,51].
4. Materials and Methods
4.1. General
The following solvents were used for paper chromatography: (1) H2 O; (2) 2% HOAc
(acetic acid: H2 O, 98:2); (3) BAW (n-BuOH–HOAc-H2 O, 4:1:5, upper layer) and (4) BBPW
(Benzene-n-BuOH–Pyridine– H2 O, 1:5:3:3, upper layer). A Shimadzu UV–Visible-1601
spectrophotometer was used to measure UV. The HRESI mass spectra were recorded on a
Finnigan LTQ FT Ultra mass spectrometer (Thermo Fisher Scientific, Bremen, Germany).
An NMR spectroscopical analysis was performed on a Brucker 400 MHz NMR spectrometer
at 400 MHz [52]. Regarding the materials, the chemicals, solvents, α-amylase, collagenase,
β-glucosidase enzymes and reference drugs (orlistat and acarbose with purities > 95%)
were obtained from Sigma-Aldrich (Merck, Darmstadt, Germany).
4.2. Plant Materials
The aerial parts of AE were collected during the flowering stage in September 2020,
from a rice field in Benha district, Qalubia governorate, Egypt. The voucher specimen (3468)
was deposited in the Herbarium of the Flora and Phytotaxonomy Research Department
(CAIM), Horticultural Research Institute, Agricultural Research Center, Giza, Egypt. The
specimen’s identity was verified by Prof. Dr. Abdel-Haleem Abdel-Mogaly, Prof. of Botany
at the Agricultural Research Centre.
4.3. Preparation of AEEE
The aerial parts of AE (2.5 kg) were extracted via refluxing with EtOH/H2 O (3:1,
3 times, each with 3 L, for 8 h). The solvent was removed under reduced pressure at 50 ◦ C
to yield a dark brown amorphous material (150 g).
4.4. Estimation of Total Phenolic and Flavonoid Contents
Folin–Ciocalteu reagent was used to measure phenolic content, which was estimated
in gallic acid equivalents (GAE) per gram of sample. Aluminum chloride (AlCl3 ) was used
to measure total flavonoid content (colorimetric assay), which was estimated in catechin
equivalents (CE) per gram of sample [52].
4.5. Isolation and Identification of Phenolics (1–5)
A portion of AEEE (70 g) was applied to a Sephadex LH 20 column (480 g) and eluted
with H2 O/MeOH mixtures of decreasing polarity to yield seven major fractions (I–VII).
Fraction I was eluted with H2 O and II with 20%, III with 40%, IV with 50%, V with 70%, VI
with 80% and VII with 90% MeOH. The collected fractions were individually subjected to
two-dimensional paper chromatography (2DPC).
Compound 1 (77 mg) was isolated in pure form from fraction II (1.8 g) via repeated
column fractionation over MCI gel (CHP-20P, 75–150 mm; Mitsubishi Chemical Co., Düsseldorf, Germany), using MeOH/H2 O mixture (20%) for elution. Compounds 2 (88 mg)
and 3 (64 mg) were individually separated from fraction IV (9.21 g) via MCI gel column
fractionation, using H2 O as solvent, followed by preparative paper chromatography (Prep.
PC), using BAW as a solvent. Compound 4 (79 mg) was isolated in pure form from 1.1 g
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of fraction V by applying repeated Sephadex LH-20 column fractionation and elution
with an H2 O–EtOH (30:70) mixture. Compound 5 (89 mg) was obtained from fraction
VII (3.35 g) through fractionation over a polyamide column and elution with a mixture of
MeOH–C6 H6 –H2 O (60:38:2).
Myricetin 3-O-β-4 C1 -(6”-O-Galloyl Glucopyranoside) 7-O-β-4 C1 Glucopyranoside, MGGG,
New Compound 1
1 H-NMR

results for 1 were as follows: flavonol moiety: 6.3 (d, J = 2.5 Hz, H-6), 6.75 (d,
J = 2.5 Hz, H-8), 7.5 (s, H20 and H-60 ), glucoside moiety at C-3: 5.35 (1H, d, J = 8.5 Hz, H-1”,
anomeric glucose at flavonol C-3), 4.26 (l H, d, J = 12 Hz, H-6”a), 4.02 (l H, m, H-6”b);
3.22-3.9 (glucoside protons overlapped with hydroxyl and water protons), galloyl moiety:
7.02 (s, H-20000 and H-60000 -galloyl protons), glucoside moiety at: C-7: 5.02 (H-1000 , anomeric
glucose at flavonol C-7). 13 C NMR results were as follows: myricetin moiety: 156.9 (C-2),
134.4 (C-3), 177.6 (C-4), 1560.8 (C-5), 99.2 (C-6), 161.6 (C-7), 94.6 (C-8), 156. (C-9), 104.5
(C-10), 121.2 (C-10 ), 109.7, (C-20 and C-60 ), 145.9 (C-30 and C-50 ), 138.9 (C-40 ); 3-O-β-glucoside
moiety: 102.9 (C-100 ), 74.4 (C-200 ), 76.5 (C-300 ), 69.8 (C-400 ), 76.6 (C-500 ), 63.3 (C-600 ); 7-O-βglucoside moiety: 99.3 (C-1000 ), 73.2 (C-2000 ), 77.2 (C-3000 ), 69.5 (C-4000 ), 76.9 (C-5000 ), 60.16
(C-6000 ); galloyl moiety: 121.9 (C-10000 ), 109.7 (C-20000 and C-60000 ), 145.5 (C-30000 and C-50000 ),
1356.8 (C-40000 ), 166.5 (C = O).
4.6. Molecular Modeling
The docking analysis was performed by using MOE 2019.0102 software [53] (Molecular
Operating Environment (MOE), 2019.01; Chemical Computing Group ULC, 1010 Sherbooke
St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2021). The binding sites were
generated from the co-crystallized ligands within the crystal protein obtained from the
Protein Data Bank (https://www.rcsb.org/, accessed on 22 August 2021) (PDB codes:
2QV4-2ZOX-2OXE) [27,28,54]. To prepare the protein for the docking experiments, water
molecules were removed. The crystallographic disorders and unfilled valence atoms
were corrected using the protein report and the utility and clean protein modules. The
protein geometry was corrected by applying the CHARMM and MMFF94 force fields.
The rigidity of the binding site was obtained by applying a fixed atom constraint. The
active site’s essential amino acids were defined and prepared for the docking process. The
structures of the tested compounds (ligands) were imported in MDL-SD file format. The
3D structures of the ligands were prepared for docking, first by protonation and then via
energy minimization by applying 0.05 RMSD kcal/mol using the CHARMM and MMFF94
force fields. The molecular docking experiment was carried out using the CDOCKER
docking engine. The receptor was held rigid, while the ligands were allowed to be flexible.
During the refinement stage, each molecule was allowed to produce ten poses with the
protein. The docking scores (-CDOCKER interaction energy) for each docking experiment
were recorded. The output from MOE 2019.0102 was further visualized with Discovery
Studio 2019 software [55]. The molecular docking algorithm was initially validated via the
redocking of the co-crystallized ligands into the active site of the respective receptors, with
the calculation of root mean square deviation (RMSD) for the reliability and reproducibility
of the proposed docking algorithm [56]. The crystal ligands of α-amylase, β-glucosidase
and pancreatic lipase were redocked, and the RMSD value, with agreement within 2.0 Å
indicating a validated algorithm, was compared to the tested compounds (1–5).
4.7. In Vitro Studies
4.7.1. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) Assay
The assay was carried out for AEEE and isolated phenolics according to BrandWilliams et al. [57].
4.7.2. Oxygen Radical Absorbance Capacity (ORAC Assay)
The antioxidant assay was applied to AEEE and the isolated phenolics [58].
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4.7.3. Reducing Power Assay
The assay was carried out on AEEE and the isolated phenolics (DeGraft-Johnson et al., 2007).
4.7.4. α-Amylase Inhibition
The assay was implemented in accordance with [50,59]. The positive control (acarbose)
and tested samples were used in a concentration range of (75–600 µg/mL). The percentage
of inhibition can be estimated using the following Equation:
100 − [{A sample/ Acontrol × 100]
4.7.5. β-Glucosidase Inhibition
The assay was performed in conformity with [60] and used the same formula for
amylase. The positive control (acarbose) and tested samples were used in a concentration
range of 75–600 µg/mL.
4.7.6. Pancreatic Lipase Inhibition
The determination of the percentage inhibition of pancreatic lipase was calculated as
prescribed by Hegazi et al. [50], using the same formula for amylase. The positive control
(orlistat) and tested samples were used in a concentration range of 12–100 µg/mL.
4.8. In Vivo Studies
4.8.1. Experimental Animals
Male Sprague-Dawley rats (170–220 g) were acquired from the National Research
Centre (NRC, Giza, Egypt). The animals were acclimatized in our animal facility for one
week before the experiment. The animals had total access to standard laboratory food
pellets and water ad libitum under temperature-controlled conditions and 12 h light-dark
cycles. The animal experiments were conducted according to the international regulations
on the usage and welfare of laboratory animals and were approved by the Ethics Committee
of the National Research Centre, Cairo, Egypt, Protocol number 49/261 (2019).
4.8.2. Acute Oral Toxicity
The acute oral toxicity of AEEE was set for male Sprague-Dawley rats according to
OECD guideline No.423 (OECD, 2001). Based on a pilot study in our laboratories, a limit
test was performed. Animals fasted overnight, and the extract was administered orally
using a gastric feeding needle at a dose of 2000 mg/kg (10 mL/kg dosing volume) [61].
4.8.3. Induction of Diabetes
Type 2 diabetes was induced via two consecutive injections of nicotinamide (NA) and
streptozotocin (STZ). The NA was dissolved in normal saline. Overnight fasted rats were
injected intraperitoneally (i.p.) with NA (110 mg/kg) 15 min before an (i.p.) injection of
a freshly prepared solution of STZ (25 mg/kg) in 0.1 M-citrate buffer (pH 4.5) (Reference
20459021). All rats were injected with STZ–NA, except the negative control rats, which
received only the vehicle, distilled water. After 6 h of NA injection, the rats were provided
with free access to glucose solution (10%, w/v) for the next 24 h. After 48 h of STZ
administration, tail vein blood was collected to determine the rats’ fasting blood glucose
levels calorimetrically (Diamond Diagnostics, Cairo, Egypt) [51]. Rats with glucose levels
over 200 mg/dL were considered diabetic and included in the study.
4.8.4. Experimental Design
Male Sprague-Dawley were randomly divided into six groups, with each group being
comprised of six rats, as follows: Group I: normal control rats (NC); Group II: normal rats
treated with AEEE (500 mg/kg) (AE 500-NC); Group III: diabetic control (DC); Group IV:
diabetic rats treated with AEEE (250 mg/kg) (AE250-DC); Group V: diabetic rats treated
with AEEE (500 mg/kg) (AE500-DC); Group VI: diabetic rats treated with the standard drug,
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glibenclamide (0.25 mg/kg). Groups I and III received only the vehicle (distilled water).
The administration of different oral doses of AEEE began 72 h after STZ injection. This
was performed using an intragastric tube for the treated group daily until the experiment
ended. Weight measurement was performed at the beginning of the study and at the end
of the 28th day. Doses were chosen based on the previous literature [37].
4.8.5. Blood and Tissue Sampling
Fasting blood glucose FBG was measured 14 and 28 d after treatment. After the 28th
day, blood samples were taken from the retro-orbital venous plexus under light ether
anesthesia after overnight fasting. Pancreatic tissues were dissected. They were washed
in ice-cold saline solution immediately. After that, they were divided into two portions.
One was homogenized in 0.1 mol/L potassium phosphate buffer (pH 7.4) using Tissue
Master TM125 (Omni International, Atlanta, GA, USA). After centrifugation at 3000 r/min
for 10 min, the clear supernatant was kept at −80 ◦ C for biochemical assays. The second
portion was placed in 10% formalin for histopathological investigation [62].
4.8.6. Assay of Biochemical Markers
Determination of Liver and Kidney Functions Markers
Serum aspartate transaminase (AST), alanine transaminase (ALT), urea and creatinine
levels were measured as kidney function tests using the kits provided by the Spectrum
Diagnostics Company (Egypt). The operational processes were measured in accordance
with the kit instructions.
Determination of Insulin and α-Amylase Activity
Insulin level was determined using an ELISA kit (CUSABIO, Wuhan, China), and
α-Amylase activity was assessed by ELitech Clinical Systems (Sèes, France).
Measurement of Serum Lipid Profile
Triacylglycerol (TAG), total cholesterol (TC) and high-density lipoprotein cholesterol
(HDL-C) were assayed calorimetrically using Reactivos GPL (Barcelona, Spain). Lowdensity lipoprotein cholesterol (LDL-C) was calculated from TAG and HDL-C values
according to Friedewald’s formula [63]:
LDL − C =( TC )−( HDL − C )−( TGs/5)
Determination of Oxidative Stress Markers in Pancreatic Tissue
Superoxide dismutase activity (SOD) was estimated in accordance with Minami and
Yoshikawa [64]. Lipid peroxidation was measured using thiobarbituric acid reactive substances (TBARS) calorimetrically [65].
4.8.7. Histopathological Investigation
The histopathologic examination was carried out on pancreas specimens (in 10%
formalin) using light microscopy. Then, samples were processed to obtain 5 µm thick
paraffin sections, followed by staining with hematoxylin and eosin (E) and observation
under a Leica photomicroscope.
4.9. Statistical Analysis
Results are expressed as means ± standard deviationss (SDs). The differences between
the various groups were analyzed using a one-way analysis of variance (ANOVA), followed
by Tukey’s post-hoc test. The level of significance was set at p-values ≤ 0.05. All analyses
were performed using the SPSS Ver. 25.0 (IBM, Chicago, IL, USA).
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5. Conclusions
This is the first study to investigate the phenolic constituents of a flowering wholeplant ethanol extract of AE, in addition to the isolation of myricetin 3-O-β-4 C1 -(600 -O-galloyl
glucopyranoside)-7-O-β-4 C1 -glucopyranoside (MGGG), which has not been reported previously in nature. According to the results, AEEE effectively improved hyperglycemia
and lipid profile while reducing oxidative stress in diabetic animals, with no signs of
toxicity. In addition, histopathological investigations demonstrated a decrease in pancreas
damage, which was aligned with the biochemical findings. This result obviously indicates
the potential efficacy of AEEE in the management of T2D. In addition, this result suggests
antioxidant activity, the inhibition of digestive enzyme actions and in vivo antidiabetic
activity as potential pathways for the AE treatment of T2D. This encourages further investigations of AEEE to discover its mechanism of action at the molecular level and the signaling
pathways involved, in addition to prospective prophylaxis against and/or curing diabetes.
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